Cue Biopharma, Inc.

NASDAQ:CUE

Biotechnology

Healthcare
$14.10 +1.42%

+$0.38 today

Market cap
$102.43M
Beta
2.53
P/E (TTM)
-6.7
EPS (TTM)
-$4.06
52W Low $4.98High $41.42

Volume 0.21M

Average 0.74M

CUE Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Cue Biopharma, Inc.NASDAQ: CUE

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables remains negative

Q1 FY2026 net receivables was $5.35M, compared with $0 a year earlier. Over 3 fiscal years it compounded at +407.4% a year.

Context

  • Net receivables amounted to 17.3% of total assets at the end of Q1 FY2026, up 17.3 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.35M-28.1% QoQ
Last fiscal yearDec 2025
$7.45M+687.8% YoY
Year agoMar 2025
$0— since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+687.8%——
3-year CAGR+407.4%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
7.45M USD
Year-over-year change
+687.8%
4-year CAGR
+24.1%

Net Receivables vs competitors

How CUE compares with its peers on the latest reported figures

  • CUE's Mar 2026 net receivables of $5.35M is the highest of the 7 companies compared; the peer median is $7.64K.
  • Net receivables amounts to 17.3% of total assets for CUE, versus a peer median of 0.0%.
CUE Competitors Peer median
Net Receivables for CUE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CUECue Biopharma, Inc.Mar 2026$5.35M —+407.4%17.3%
OTLKOutlook Therapeutics, Inc.Mar 2026$2.72M ——12.4%
NRXPNRx Pharmaceuticals, Inc.Mar 2026$181K —+184.4%1.5%
COEPCoeptis Therapeutics, Inc.Mar 2026$15.29K —-3.1%0.1%
IPSCCentury Therapeutics, Inc.Mar 2026$0 -100.0%-5.1%0.0%
SPRBSpruce Biosciences, Inc.Mar 2026$0 ——0.0%
EQEquillium, Inc.Mar 2026$0 -100.0%-70.3%0.0%
Peer median (excluding CUE) $7.64K-100.0%-4.1%0.0%

Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents64.37M51.61M48.51M22.46M27.14M
Short-term Investments024.68M0929K0
Net Receivables3.14M57K1.7M945K7.45M
Inventory00000
Other Current Assets80K841K1.24M805K2.4M
Total Current Assets68.47M77.19M51.45M25.14M36.98M
Property, Plant & Equipment (Net)11.92M10.7M7.12M4.84M4.32M
Goodwill00000
Intangible Assets00000
Long-term Investments150K0151K0154K
Tax Assets00000
Other Non-current Assets2.86M3.39M2.81M2.21M760K
Total Non-current Assets14.93M14.1M10.08M7.05M5.23M
Total Assets83.4M91.28M61.53M32.19M42.21M
Account Payables2.59M2.73M3.5M2.82M3.95M
Short-term Debt1.97M1.96M3.96M4.33M0
Tax Payables00000
Deferred Revenue645.35K02.11M05.34M
Other Current Liabilities38.31K2.27M1.92M85K783K
Total Current Liabilities12.79M11.55M17.08M13.69M13.49M
Long-term Debt08.04M4.2M00
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00010
Total Non-current Liabilities5.12M14.05M7.36M1M2.29M
Total Liabilities17.91M25.6M24.45M14.69M15.78M
Common Stock32.2K43K47K62K97K
Retained Earnings(197.45M)(250.46M)(301.19M)(341.86M)(368.47M)
Accumulated OCI0(96K)000
Other Stockholders Equity00000
Minority Interest00000
Total Equity65.49M65.68M37.09M17.5M26.43M
Total Debt12.02M19.32M14.7M8.88M4.2M
Net Debt(52.35M)(32.3M)(33.82M)(13.58M)(22.94M)

Cue Biopharma, Inc.

NASDAQ:CUE

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.